Physician profile
Tony Bui
NPI 1225323785
$6,588.85
in general payments reported to CMS, 2019-2025
38 companies · $549 in 2025
The $549 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,176 · 2020: $945 · 2021: $656 · 2022: $514 · 2023: $746 · 2024: $1,001 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,296.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $906.07 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $807.02 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $698.33 | 2019-2025 | Belbuca, Xtampza |
| Nevro Corp. | $594.51 | 2019-2024 | Senza |
| Abbott Laboratories | $505.85 | 2020-2024 | Proclaim, Eterna |
| Boston Scientific Corporation | $425.55 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Nalu Medical, INC. | $394.05 | 2021-2024 | Nalu Neurostimulation System |
| Medtronic, INC. | $328.80 | 2022-2025 | Inceptiv |
| Daiichi Sankyo INC. | $238.91 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $229.02 | 2019-2021 | |
| Mdd US Operations, LLC | $141.97 | 2019 | |
| Sentynl Therapeutics, INC. | $135.09 | 2019 | |
| Saluda Medical Americas, INC. | $123.54 | 2024-2025 | Evoke |
| Allergan, INC. | $122.49 | 2019-2022 | |
| Pfizer INC. | $118.96 | 2019-2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $106.86 | 2019-2021 | |
| Vertiflex, INC. | $81.30 | 2019 | |
| Ibsa Pharma INC. | $72.95 | 2023-2025 | Licart, Tirosint, Tirosint |
| West Therapeutics Development, LLC | $61.47 | 2019 | |
| Fidia Pharma USA INC. | $55.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $43.67 | 2019-2021 | |
| Spr Therapeutics, INC | $37.22 | 2019 | |
| Biotronik Nro, INC. | $36.68 | 2024-2025 | Prospera |
| Vertos Medical, INC. | $35.72 | 2024 | Mild Device Kit |
| Zyla Life Sciences, INC. | $30.09 | 2019-2020 | |
| Lilly USA, LLC | $29.78 | 2019 | |
| Almatica Pharma LLC | $29.57 | 2021 | |
| Arbor Pharmaceuticals, INC. | $25.76 | 2019-2020 | |
| Forte Bio-Pharma LLC | $25.42 | 2019 | |
| Electronic Waveform Lab, INC. | $25.16 | 2019-2021 | |
| Lundbeck LLC | $21.62 | 2025 | Vyepti |
| Vertex Pharmaceuticals Incorporated | $18.22 | 2025 | |
| Redhill Biopharma INC. | $17.44 | 2021 | |
| Bioventus LLC | $14.67 | 2021 | |
| Medtronic USA, INC. | $14.25 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.59 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.79 | 2020 | |
| Orthofix Medical, INC. | $8.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.